Back to Clinical Trials

Vilon

KE, L-Lys-L-Glu, lysylglutamic acid

Quick Stats

Studies 40

Trials 100

Overview Studies Clinical Trials

Recruiting NA INTERVENTIONAL NCT05923255

LISH Trial for the Hepatic Flexure and Proximal Transverse Colon Cancer

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

The goal of this clinical trial is to compare the long-term outcomes of Laparoscopic Ileocecal-Sparing Right Hemicolectomy(LISH) compared to traditional laparoscopic right hemicolectomy(TRH) in the treatment of hepatic flexure colon cancer and proximal transverse colon cancer.

Detailed Description

This study is a prospective, multicenter, open-labeled, randomized controlled clinical trial. The enrolled patients will be randomly assigned to either the LISH or TRH group in a 1:1 ratio and will receive the corresponding surgery. The primary endpoint: 3-year disease free survival. The second endpoint: (1)90-day postoperative complications; (2)Pathology-related indicators, including positive margin rate, number of harvested lymph nodes and lymph node metastasis rate;(3) 5-year overall survival rate (OS)

Interventions

Name: LISH （Laparoscopic Ileocecal-Sparing Right Hemicolectomy）

Type: PROCEDURE

Description: Preserve the ileocolic blood vessels, and perform dissection of lymph node groups 203, 202, and 201d along the root of ICV(Ileocolic artery)/ICA(Ileocolic vein). Group 201d lymph nodes are defined as the distal lymph nodes of the ileocolic vessels (colonic branch). Use an intracavitary cutting and sealing device to transect the proximal colon along the predetermined margin, and transect the transverse colon at 10cm distal to the tumor. Perform ileocecal-transverse colonic anastomosis.

Name: TRH（Traditional Laparoscopic Right Hemicolectomy）

Type: PROCEDURE

Description: Transect the root of the ileocolic vessels and perform dissection of lymph node groups 203, 202, and 201; sever the roots of the right colic and middle colic vessels, and clear the surrounding lymphoadipose tissue (lymph node groups 211/212/213 and 221/222/223). Transect the transverse colon 10cm distal to the tumor and cut the terminal ileum 10cm from the ileocecal junction. Perform ileum-to-transverse colon anastomosis.

Primary Outcomes

Measure: 3-year disease free survival

TimeFrame: 3 years

Description: the time from enrollment until disease relapse or death from any cause 3 years after surgery

Trial Information

NCT ID

NCT05923255

Status

Recruiting

Study Type

INTERVENTIONAL

Phases

Sponsor

Zhejiang University

Last Updated

December 15, 2025